furmonertinib + pemetrexed + carboplatin + bevacizumab

This is a combination regimen consisting of four drugs: **Furmonertinib** is a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor that selectively targets both EGFR-sensitizing and T790M resistance mutations, primarily used in the treatment of non-small cell lung cancer (NSCLC). **Pemetrexed** is an antifolate antineoplastic agent that inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, leading to inhibition of DNA and RNA synthesis. **Carboplatin** is a platinum-based chemotherapeutic agent that causes DNA crosslinking and apoptosis. **Bevacizumab** is a monoclonal antibody targeting vascular endothelial growth factor A (VEGF-A), inhibiting angiogenesis required for tumor growth. This combination regimen has been investigated as first-line or subsequent therapy for advanced or metastatic non-squamous NSCLC, particularly in patients with EGFR mutations or after progression on prior EGFR TKI therapy[1][6][7]. The rationale for this combination includes targeting tumor proliferation via multiple mechanisms—EGFR inhibition, cytotoxic chemotherapy, and antiangiogenic blockade.

Brand names

Alflutinib (for furmonertinib, in China)Alimta (for pemetrexed)Avastin (for bevacizumab)

Other names

none